Biotricity is trading $0.13 (+7.62%) now, with no clearly reported company-specific catalyst for August 24, 2026.

  • The August 19 Form 10-Q showed higher revenue but a wider net loss, substantial going-concern doubt, and significant working-capital needs; it did not connect those results to the current move.
  • Broader U.S. indexes are mixed to lower, so market sentiment does not clearly explain the gain.